title: Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003.
abstract: Following a large Neisseria meningitidis W135 (NmW135) epidemic in Burkina Faso (BF) during 2002, a newly licensed trivalent A/C/W135 meningococcal polysaccharide vaccine was introduced in 2003. We conducted a case-control study to assess the vaccine effectiveness (VE) against meningococcal disease. Thirty-two N. meningitidis A (NmA) and 3 NmW135 meningitis cases were enrolled and matched by age-neighborhood to 103 controls. After adjusting for confounding risk factors, VE against NmA or NmW135 was 83.6% (95% CI 31.8-97.0, p=0.01) for persons with verified vaccination. VE against probable/definite NmA alone was 94.0% (95% CI 58.7-99.0, p=0.0003). Low number of NmW135 cases did not allow estimation of VE against NmW135 alone. The vaccine was highly effective against the epidemic. Since 2003, the trivalent vaccine continues to be effectively used in Africa for the control of meningococcal disease epidemics.
authors.affiliation: GlaxoSmithKline (GSK) Biologicals, Rue Institut 89, Rixensart, Belgium. montse.soriano@gskbio.com
authors.forename: Montse
authors.initials: M
authors.lastname: Soriano-Gabarró
authors.forename: Laurent
authors.initials: L
authors.lastname: Toé
authors.forename: Sylvestre R M
authors.initials: SR
authors.lastname: Tiendrebeogo
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Nelson
authors.forename: Moumouni
authors.initials: M
authors.lastname: Dabal
authors.forename: Mamoudou H
authors.initials: MH
authors.lastname: Djingarey
authors.forename: Brian
authors.initials: B
authors.lastname: Plikaytis
authors.forename: Nancy
authors.initials: N
authors.lastname: Rosenstein
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D002050:Burkina Faso; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D006801:Humans; D008585:Meningitis, Meningococcal / Q000097:blood / Q000276:immunology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D038582:Neisseria meningitidis, Serogroup W-135 / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D011159:Population Surveillance / Q000379:methods; D015610:Serum Bactericidal Test; D016896:Treatment Outcome
chemical_list: D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial